Rigel highlights GAVRETO data at ESMO Congress 2026
Rigel says it will present new pralsetinib data in oral and poster presentations on RET fusion-positive cancers at the ESMO Congress 2026.
Site Search
Search market news
Find public news by keyword, exact ticker, category and date.
Matching instruments
Open a ticker page for its news coverage. The news search below stays a text search.
News Feed
2 results loaded, newest first. End of these results.
Rigel Highlights GAVRETO Data at ESMO Congress
Rigel said it presented pooled efficacy and safety data from two clinical trials of GAVRETO in RET fusion-positive cancers at ESMO Congress 2026.